Key result
Angiopoietin-like protein 2 (ANGPTL2) exhibits a dual function in cancer pathology, acting as a tumor promoter when derived from tumor cells and a tumor suppressor when derived from tumor stroma.
Why the study?
ANGPTL2 exhibits dual functions as both a tumor promoter and tumor suppressor, complicating the development of therapeutic strategies targeting it.
The dual role of ANGPTL2 in the tumor microenvironment complicates the development of targeted therapeutic strategies.
Stromal ANGPTL2 effects in the TME remain unclear; leaves open its net contribution to progression and any therapeutic targeting.
The tumor microenvironment is composed of tumor cells and various stromal cell types, such as immune cells, fibroblasts, and vascular cells. Signaling interactions between tumor and stromal cells orchestrate the tumor microenvironment's contribution to tumor progression. Angiopoietin-like protein 2 (ANGPTL2) is a secreted glycoprotein homologous to angiopoietins. Previous studies indicate that tumor cell-derived ANGPTL2 serves as a tumor promoter. However, recent studies suggest that tumor stroma-derived ANGPTL2 shows tumor-suppressive activity by enhancing anti-tumor immune responses, supporting a dual function for ANGPTL2 in cancer pathology. Such complexity can complicate development of effective therapeutic strategies targeting ANGPTL2. In this Review, we focus on ANGPTL2 activity in the tumor microenvironment and its function in anti-cancer immunity.
No takes yet. Share an insight, caveat, or question.
Horiguchi et al. (2024) conducted a review in Cancer. Angiopoietin-like protein 2 (ANGPTL2) was evaluated. Angiopoietin-like protein 2 (ANGPTL2) exhibits a dual function in cancer pathology, acting as a tumor promoter when derived from tumor cells and a tumor suppressor when derived from tumor stroma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: